Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Neurol. 2012 Nov;32(5):491-9. doi: 10.1055/s-0033-1334467. Epub 2013 May 15.

Inflammatory and toxic myopathy.

Author information

  • 1Department of Neurology, University of Michigan Health System, Ann Arbor, Michigan 48109-5036, USA. jteener@med.umich.edu

Abstract

Although muscle diseases are relatively rare, several treatable myopathies must be recognized by the clinician to maximize the possibility of restoring strength in affected patients. The inflammatory myopathies, including polymyositis, dermatomyositis, inflammatory necrotizing myopathy, and myositis in association with mixed connective tissue disease, typically respond well to immunosuppressive treatment. Inclusion body myositis, a myopathy that has features of both inflammation and primary degeneration, may not be treatable at this time, but treatments are actively being sought. Muscle dysfunction caused by toxins must also be recognized because removal of the offending toxin usually results in restoration of normal muscle function. Important muscle toxins include cholesterol-lowering medications, colchicine, zidovudine, corticosteroids, emetine, and ethanol.

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

PMID:
23677656
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk